中南大学湘雅医院
Xiangya Hospital
在本站收录的 53 种疾病中,这家医院列在其中 39 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
中南大学湘雅医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma63 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma119 篇牵头论文牵头 3 项开放试验
- 胃癌Stomach cancer35 篇牵头论文
- 肝母细胞瘤Hepatoblastoma5 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
- 脊索瘤Chordoma1 篇牵头论文
- 骨肉瘤Osteosarcoma15 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour4 篇牵头论文牵头 1 项开放试验
- 神经母细胞瘤Neuroblastoma4 篇牵头论文
- 尤文肉瘤Ewing sarcoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma8 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia4 篇牵头论文
- 再生障碍性贫血Aplastic anaemia3 篇牵头论文
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis1 篇牵头论文
- β 地中海贫血Beta thalassaemia1 篇牵头论文
- 血友病 AHaemophilia A1 篇牵头论文
- 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome0 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura2 篇牵头论文
- 范可尼贫血Fanconi anaemia1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder5 篇牵头论文
- IgG4相关性疾病IgG4-related disease1 篇牵头论文
- 重症肌无力Myasthenia gravis20 篇牵头论文
- 烟雾病Moyamoya disease6 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis23 篇牵头论文
- 脊髓性肌萎缩症Spinal muscular atrophy2 篇牵头论文
- 法布雷病Fabry disease0 篇牵头论文
- 庞贝病Pompe disease0 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy3 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- Alport 综合征Alport syndrome0 篇牵头论文
- IgA 肾病IgA nephropathy4 篇牵头论文
- 成骨不全症Osteogenesis imperfecta1 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 63 篇,占 2.6%。
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
- 分期
- III期
- 开始
- 2026-07
- 登记号
- NCT07661771
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 6 家列出的医院为研究中心东莞、中山、佛山、广州、深圳、长沙
- 正在招募QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- 分期
- III期
- 开始
- 2025-05
- 登记号
- NCT06749899
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙
- 正在招募LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
- 分期
- II期
- 开始
- 2025-01
- 登记号
- NCT06788002
年龄 18 岁 至 70 岁(登记的条件)
牵头:湖南省肿瘤医院;另有 2 家列出的医院为研究中心长沙
- 正在招募A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- 分期
- II期
- 开始
- 2025-04
- 登记号
- NCT06839066
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙
- 正在招募Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
- 分期
- II期
- 开始
- 2025-06
- 登记号
- NCT07070479
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心中山、广州、珠海、长沙
- 正在招募喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07311772
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙
- 正在招募Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07328841
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心中山、南宁、广州、梧州、武汉、汕头、珠海、长沙
- 正在招募40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07328854
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙
- 正在招募Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- 分期
- III期
- 开始
- 2024-03
- 登记号
- NCT06239727
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文63
- A11 Peptide Enhances Radiosensitivity by Degrading EphA2 in Nasopharyngeal Carcinoma.
- A Novel Peculiarity of TXNIP Reversing the Radioresistance of NPC and Inducing Ferroptosis by xCT-GSH-GPX4-ROS Axis.
- Vinburnine Sensitizes Radiotherapy Efficacy in Nasopharyngeal Carcinoma by Triggering Pyroptosis and Immune Responses via Activation of EDAR-NFκB Pathway.
- Deacetylation of TALDO1 by HDAC6 promotes glycolysis and nasopharyngeal carcinoma progression through a moonlighting function.
- HAT1/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma.
- Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma.
- Chemoradiotherapy Strategies for Immunotherapy-Sensitive Multi-Metastatic Nasopharyngeal Carcinoma: A Comparative Case Report and Literature Review.
- Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost-effectiveness analysis.
- USP5 Binds and Stabilizes EphA2 to Increase Nasopharyngeal Carcinoma Radioresistance.
- Ferroptosis inhibition via the ROS-GPX4 axis drives microplastic-induced malignant progression of nasopharyngeal carcinoma.
- ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance.
- HDAC1/2-mediated deacetylation of KLF9 promotes the malignant progression of nasopharyngeal carcinoma via CDH17.
- The dynamic changes of glymphatic function at different post-radiotherapy stages in patients with nasopharyngeal carcinoma.
- Multiparameter diagnostic model using S100A9, CCL5 and blood biomarkers for nasopharyngeal carcinoma.
- Financial toxicity-related factors in patients with nasopharyngeal carfcinoma: a cross-sectional study.
- Malnutrition Indicate Poor Clinical Outcome in Patients With NPC: A Multicenter Cohort Study.
- Classifications of Postradiation Nasopharyngeal Necrosis for Guiding Transnasal Endoscopic Nasopharyngeal Skull Base Surgery.
- CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma.
- Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma.
- HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinoma.
- Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein.
- Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
- ANXA6 expression as a potential indicator of tumor diagnosis, metastasis and immunity in nasopharyngeal carcinoma.
- LncRNA BC200 promotes the development of EBV-associated nasopharyngeal carcinoma by competitively binding to miR-6834-5p to upregulate TYMS expression.
- Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma.
- CT-based peritumoral radiomics nomogram on prediction of response and survival to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
- Epstein-Barr virus-driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma.
- Transcriptional pausing induced by ionizing radiation enables the acquisition of radioresistance in nasopharyngeal carcinoma.
- Amide proton transfer (APT) and magnetization transfer (MT) in predicting short-term therapeutic outcome in nasopharyngeal carcinoma after chemoradiotherapy: a feasibility study of three-dimensional chemical exchange saturation transfer (CE
- HDAC4 mediated LHPP deacetylation enhances its destabilization and promotes the proliferation and metastasis of nasopharyngeal carcinoma.
- Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axis.
- Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma.
- The effects of doxorubicin loaded aptamer S3-linked DNA tetrahedrons on nasopharyngeal carcinoma.
- A two-stage genome-wide association study identifies novel germline genetic variations in CACNA2D3 associated with radiotherapy response in nasopharyngeal carcinoma.
- Radiosensitization of Nasopharyngeal Carcinoma by Graphene Oxide Nanosheets to Reduce Bcl-2 Level.
- Proteomics Profiling Reveals the Molecular Signatures and Potential Therapeutic Targets of Human Nasopharyngeal Carcinoma.
- CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma.
- MFSD4A inhibits the malignant progression of nasopharyngeal carcinoma by targeting EPHA2.
- CircTMTC1 contributes to nasopharyngeal carcinoma progression through targeting miR-495-MET-eIF4G1 translational regulation axis.
- Salvage Endoscopic Skull Base Surgery: Another Treatment Option After Immunotherapy for Recurrent Nasopharyngeal Carcinoma.
- Radiosensitizer EXO-miR-197-3p Inhibits Nasopharyngeal Carcinoma Progression and Radioresistance by Regulating the AKT/mTOR Axis and HSPA5-mediated Autophagy.
- TBL1X and Flot2 form a positive feedback loop to promote metastasis in nasopharyngeal carcinoma.
- PGC1α-mediated fatty acid oxidation promotes TGFβ1-induced epithelial-mesenchymal transition and metastasis of nasopharyngeal carcinoma.
- A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma.
- Efficacy of chemoradiotherapy in survival of stage Ⅳ nasopharyngeal carcinoma and establishment of a prognostic model.
- Pathogenesis and Diagnostic Significance of EBV-miR-BARTs in Nasopharyngeal Carcinoma.
- Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
- Neutrophil-to-lymphocyte ratio trend: A novel prognostic predictor in patients with nasopharyngeal carcinoma receiving radiotherapy.
- Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma.
- CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK.
- Flotillin-2 promotes cell proliferation via activating the c-Myc/BCAT1 axis by suppressing miR-33b-5p in nasopharyngeal carcinoma.
- The efficacy of locoregional radiotherapy plus chemotherapy vs. chemotherapy alone in metastatic nasopharyngeal carcinoma: a meta-analysis.
- Curcumol inhibits EBV-positive Nasopharyngeal carcinoma migration and invasion by targeting nucleolin.
- EBV-LMP1 promotes radioresistance by inducing protective autophagy through BNIP3 in nasopharyngeal carcinoma.
- LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma.
- The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients.
- Magnetic resonance imaging-based radiogenomics analysis for predicting prognosis and gene expression profile in advanced nasopharyngeal carcinoma.
- Reply: Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma: Methodological issues.
- The role of Exosomes in the Pathogenesis of Nasopharyngeal Carcinoma and the involved Clinical Application.
- Brain-Specific Relative Biological Effectiveness of Protons Based on Long-term Outcome of Patients With Nasopharyngeal Carcinoma.
- Galectin‑3 facilitates the proliferation and migration of nasopharyngeal carcinoma cells via activation of the ERK1/2 and Akt signaling pathways, and is positively correlated with the inflammatory state of nasopharyngeal carcinoma.
- CircRNA circTRAF3 promotes nasopharyngeal carcinoma metastasis through targeting miR-203a-3p/AKT3 axis.
- Paradoxical effects of DNA tumor virus oncogenes on epithelium-derived tumor cell fate during tumor progression and chemotherapy response.
中文论文(未计入)3
- Causes of missed MRI diagnosis of radiotherapy-induced temporal lobe injury in nasopharyngeal carcinoma.
- [Application of temporalis muscle flap in repair and reconstruction after the resection of tumor or necrotic foci following radiotherapy of nasopharyngeal carcinoma].
- [Clinical study on endoscopic surgery for soft tissue necrosis of cranial base after radiotherapy for nasopharyngeal carcinoma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
- Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
- Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma
- Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
- Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
- TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images
- PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
- Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
- PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
PubMed 以外找到的论文(未计入)49
- 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial
- Bionic nanobombs target nasopharyngeal carcinoma to enhance the efficacy of chemoradiotherapy by destroying DNA damage repair systems
- CircARHGAP12 suppresses cisplatin-induced alkaliptosis in nasopharyngeal carcinoma through G3BP1-mediated upregulation of CA9 in an RNA G-quadruplex-dependent manner
- Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.
- Optimization of the 9th Ajcc/Uicc Tnm Staging System for Nasopharyngeal Carcinoma Based on Age and Pretreatment Ebv DNA: Exploring Prognostic Stratification and Individualized Treatment Strategies for Stage Ii-Iii Patients
- PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized
- 153P Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
- Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
- Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.
- Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.
- Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial
- PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.
- Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study.
- RETRACTED: METTL14 Promotes Lipid Metabolism Reprogramming and Sustains Nasopharyngeal Carcinoma Progression via Enhancing m6A Modification of ANKRD22 mRNA
- SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment
- CACA guidelines for holistic integrative management of nasopharyngeal carcinoma
- Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1
- PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 11 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 12 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 13 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 14 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 15 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 16 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 17 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 2 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK
- Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 3 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK
- Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop
- Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Fabrication of metformin and survivin siRNA encapsulated into polyethyleneimine-altered silk fibroin nanoparticles for the treatment of nasopharyngeal carcinoma
- Functional Characterization of p53 in NPC C666-1 Cells by CRISPR-Based Gene Knockout and Transcriptome Sequencing
- 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
- Additional file 1 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2
- Additional file 2 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2
- Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.
- Elevated transcriptional pausing of RNA polymerase II underlies acquired resistance to radiotherapy
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
- Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
- [Retracted] MicroRNA‑214 promotes proliferation and inhibits apoptosis via targeting Bax in nasopharyngeal carcinoma cells
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文8
- Shared chemoresistance genes in ESCC and cervical Cancer: Insights from pharmacogenomics and Mendelian randomization.
- MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction.
- Prognostic and clinical significance of tumor-associated macrophages in esophageal squamous cell carcinoma after surgery: do biomarkers and distributions matter?
- Classification and prediction of chemoradiotherapy response and survival from esophageal carcinoma histopathology images.
- Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.
- OPN Promotes Cell Proliferation and Invasion through NF-κB in Human Esophageal Squamous Cell Carcinoma.
- Reduced LINC00551 expression promotes proliferation and invasion of esophageal squamous cancer by increase in HSP27 phosphorylation.
- Silencing of UAP1L1 inhibits proliferation and induces apoptosis in esophageal squamous cell carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
PubMed 以外找到的论文(未计入)7
- PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma
- Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study
- Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study
- MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
- Radiotherapy for Esophageal Squamous Cell Carcinoma Concomitant With Hypoproteinemia: a Case Report
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 119 篇,占 0.8%。
长沙有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
- 分期
- 未注明
- 开始
- 2023-05
- 登记号
- NCT06746701
年龄 18 岁 至 65 岁(登记的条件)
牵头:中南大学湘雅医院;另有 1 家列出的医院为研究中心广州、长沙
- 正在招募Antiviral Therapy for Patients With Liver Cancer After Surgery
- 分期
- 未注明
- 开始
- 2021-12
- 登记号
- NCT05466565
年龄 18 岁 至 65 岁(登记的条件)
牵头:中南大学湘雅医院长沙
- 邀请入组JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
- 分期
- I期
- 开始
- 2025-07
- 登记号
- NCT06882876
年龄 18 岁 至 75 岁(登记的条件)
牵头:中南大学湘雅医院长沙
- 正在招募Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- 分期
- III期
- 开始
- 2023-05
- 登记号
- NCT05862337
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文119
- Quantitative Assessment of Peritumoral Stiffness Using Shell Elastography Enhances the Differentiation of Hepatocellular Carcinoma From Metastatic Liver Carcinoma.
- Integrative Multi-Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN-2, a Covalent FGFR Inhibitor.
- Gamma-glutamyltransferase and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta‑analysis and systematic review.
- Primary liver cancer disease burden in Cambodia during 1990-2021: a systematic analysis of datasets from the global burden of disease study 2021.
- Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective.
- The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ.
- CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R/JAK2/STAT3 positive feedback loop.
- SLC7A11, a disulfidptosis-related gene, correlates with multi-omics prognostic analysis in hepatocellular carcinoma.
- A Novel Signature Composed of Hypoxia, Glycolysis, Lactylation Related Genes to Predict Prognosis and Immunotherapy in Hepatocellular Carcinoma.
- Deubiquitylating Enzymes in Hepatocellular Carcinoma.
- Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis.
- LncRNA FTX accelerates the progression of hepatocellular carcinoma by FTX/miR-374a-3p/HMGB1 pathway.
- CDC5L binds to ELAVL1 to inhibit pyroptosis in hepatocellular carcinoma through the Caspase 3/GSDME signaling pathway.
- USP2-mediated PPARγ stabilization promotes hepatocellular carcinoma progression and M2 macrophage polarization via oleic acid.
- Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study.
- MRI Tomoelastography to Assess the Combined Status of Vessels Encapsulating Tumor Clusters and Microvascular Invasion in Hepatocellular Carcinoma.
- The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma.
- Comprehensive analysis reveals the prognostic and immunological role of PSMD13 in hepatocellular carcinoma.
- The molecular characteristics of DNA damage and repair related to P53 mutation for predicting the recurrence and immunotherapy response in hepatocellular carcinoma.
- Long noncoding RNA semaphorin 6A-antisense RNA 1 reduces hepatocellular carcinoma by promoting semaphorin 6A mRNA degradation.
- BRCC36 Deubiquitinates HMGCR to Regulate the Interplay Between Ferroptosis and Pyroptosis.
- CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation.
- Arvanil induces ferroptosis of hepatocellular carcinoma by binding to MICU1.
- A Novel Amino Acid-Related Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma.
- The survival prediction analysis and preliminary study of the biological function of YEATS2 in hepatocellular carcinoma.
- ARL8B promotes hepatocellular carcinoma progression and inhibits antitumor activity of lenvatinib via MAPK/ERK signaling by interacting with RAB2A.
- Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study.
- Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
- UCHL3 inhibits ferroptosis by stabilizing β-catenin and maintains stem-like properties of hepatocellular carcinoma cells.
- Comprehensive molecular classification predicted microenvironment profiles and therapy response for HCC.
- Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.
- Spatial patterns and MRI-based radiomic prediction of high peritumoral tertiary lymphoid structure density in hepatocellular carcinoma: a multicenter study.
- Deep learning based automatic internal gross target volume delineation from 4D-CT of hepatocellular carcinoma patients.
- The comprehensive roles of lncRNA FAM99A/FAM99B in hepatocellular carcinoma: Expressions, regulatory mechanisms and functional pathway analysis.
- A novel CD8+ T cell-related gene signature as a prognostic biomarker in hepatocellular carcinoma.
- Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT.
- Development of tryptophan metabolism patterns to predict prognosis and immunotherapeutic responses in hepatocellular carcinoma.
- miR-195-5p Targets CDK1 To Regulate New DNA Synthesis and Inhibit the Proliferation of Hepatocellular Carcinoma Cells.
- Tumor-stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma.
- Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma.
- Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
- Acyl-CoA thioesterase 12 suppresses YAP-mediated hepatocarcinogenesis by limiting glycerolipid biosynthesis.
- Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.
- Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.
- Competing risk model for prognostic comparison between clear cell type and common type hepatocellular carcinoma: A population-based propensity score matching study.
- Hepatic stellate cell-released CXCL1 aggravates HCC malignant behaviors through the MIR4435-2HG/miR-506-3p/TGFB1 axis.
- The deubiquitinase EIF3H promotes hepatocellular carcinoma progression by stabilizing OGT and inhibiting ferroptosis.
- Hepatocellular carcinoma cells remodel the pro-metastatic tumour microenvironment through recruitment and activation of fibroblasts via paracrine Egfl7 signaling.
- Sorcin regulate pyroptosis by interacting with NLRP3 inflammasomes to facilitate the progression of hepatocellular carcinoma.
- USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through β-catenin stabilization.
- RNF2 inhibits E-Cadherin transcription to promote hepatocellular carcinoma metastasis via inducing histone mono-ubiquitination.
- A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma.
- Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.
- WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability.
- Circ_0003747 promotes thyroid cancer progression by sponging miR-338-3p to upregulate PLCD3 expression.
- The Hepatic Nerves Regulated Inflammatory Effect in the Process of Liver Injury: Is Nerve the Key Treating Target for Liver Inflammation?
- Evaluation of the efficacy and safety of CalliSpheres® microsphere-transarterial chemoembolization in large hepatocellular carcinoma.
- DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway.
- Noninvasive Visualization of Sub-5 mm Orthotopic Hepatic Tumors by a Nanoprobe-Mediated Positive and Reverse Contrast-Balanced Imaging Strategy.
- Identification of ACSF gene family as therapeutic targets and immune-associated biomarkers in hepatocellular carcinoma.
- The comprehensive expression and functional analysis of m6A modification "readers" in hepatocellular carcinoma.
- The bioinformatics and experimental analysis of the novel roles of virus infection-associated gene CDC20 for prognosis and immune infiltration in hepatocellular carcinoma.
- Clinical utility of serum fucosylated fraction of alpha-fetoprotein in the diagnostic of hepatocellular carcinoma: a comprehensive analysis with large sample size.
- A comprehensive analysis of FOX family in HCC and experimental evidence to support the oncogenic role of FOXH1.
- Integrative bioinformatics and experimental analysis revealed TEAD as novel prognostic target for hepatocellular carcinoma and its roles in ferroptosis regulation.
- An M0 macrophage-related prognostic model for hepatocellular carcinoma.
- Prognostic Values of BolA Family Member Expression in Hepatocellular Carcinoma.
- LncRNA FIRRE promotes the proliferation and metastasis of hepatocellular carcinoma by regulating the expression of PXN through interacting with MBNL3.
- The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma.
- Sevoflurane Inhibits Metastasis in Hepatocellular Carcinoma by Inhibiting MiR-665-Induced Activation of the ERK/MMP Pathway.
- Exosomal microRNA-25 released from cancer cells targets SIK1 to promote hepatocellular carcinoma tumorigenesis.
- Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.
- G Protein-Coupled Receptor Kinase 4 Is a Novel Prognostic Factor in Hepatocellular Carcinoma.
- Single-Cell RNA-seq Analysis Reveals Dysregulated Cell-Cell Interactions in a Tumor Microenvironment Related to HCC Development.
- The Dysregulation of SOX Family Correlates with DNA Methylation and Immune Microenvironment Characteristics to Predict Prognosis in Hepatocellular Carcinoma.
- Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
- Systematic pan-cancer analysis identifies RALA as a tumor targeting immune therapeutic and prognostic marker.
- Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.
- Prognostic stratification based on m5C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma.
- Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism.
- New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
- Pantothenate Kinase 1 Inhibits the Progression of Hepatocellular Carcinoma by Negatively Regulating Wnt/β-catenin Signaling.
- Tryptophan-sorbitol based carbon quantum dots for theranostics against hepatocellular carcinoma.
- VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
- Circular RNA circ_GLIS2 suppresses hepatocellular carcinoma growth and metastasis.
- PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma.
- The potential of CircRNA1002 as a biomarker in hepatitis B virus-related hepatocellular carcinoma.
- Analysis of mutations in DNA damage repair pathway gene in Chinese patients with hepatocellular carcinoma.
- Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma.
- A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection.
- Automated machine learning for differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma on multiphasic MRI.
- Role of CD68 in tumor immunity and prognosis prediction in pan-cancer.
- Proteomic analysis of small extracellular vesicles from the plasma of patients with hepatocellular carcinoma.
- YTH domain family: potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma.
- Integrated analysis of expression, prognostic value and immune infiltration of GSDMs in hepatocellular carcinoma.
- Six genes involved in prognosis of hepatocellular carcinoma identified by Cox hazard regression.
- Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma.
- Loss of androgen receptor promotes HCC invasion and metastasis via activating circ-LNPEP/miR-532-3p/RAB9A signal under hypoxia.
- Long Noncoding RNA TRIM52-AS1 Sponges miR-514a-5p to Facilitate Hepatocellular Carcinoma Progression Through Increasing MRPS18A.
- STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFβ signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma.
- NAD(P)HX epimerase downregulation promotes tumor progression through ROS/HIF-1α signaling in hepatocellular carcinoma.
- GNA14's interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK/JNK and PI3K/AKT signaling pathway.
- Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
- BTB/POZ domain-containing protein 7/hypoxia-inducible factor 1 alpha signalling axis modulates hepatocellular carcinoma metastasis.
- EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics.
- Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients
- Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
- Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
- Integrative Transcriptomic, Proteomic and Functional Analysis Reveals ATP1B3 as a Diagnostic and Potential Therapeutic Target in Hepatocellular Carcinoma.
- A new survival model based on ion channel genes for prognostic prediction in hepatocellular carcinoma.
- The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.
- The strategy and efficacy of prophylaxis against hepatitis B virus recurrence after liver transplantation for HBV-related diseases in the era of potent nucleos(t)ide analogues: A meta-analysis.
- Atractylenolide III predisposes miR-195-5p/FGFR1 signaling axis to exert tumor-suppressive functions in liver cancer.
- Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC.
- Hepatic macrophages: Key players in the development and progression of liver fibrosis.
- Microvascular invasion, an important clinical feature that should be deeply explored in hepatocellular carcinoma.
- ATE1 Inhibits Liver Cancer Progression through RGS5-Mediated Suppression of Wnt/β-Catenin Signaling.
- Deregulated 14-3-3ζ and methionine adenosyltransferase α1 interplay promotes liver cancer tumorigenesis in mice and humans.
- Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
- JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
- Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
- Antiviral Therapy for Patients With Liver Cancer After Surgery
- An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC
- Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
- Thermal Ablation Followed by Immunotherapy for HCC
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
- A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 4 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- 分期
- 未注明
- 开始
- 2023-09
- 登记号
- NCT06035250
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛
- 正在招募A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2022-01
- 登记号
- NCT05150691
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文35
- Enhancing gastric ultrasound training with standardized patient-based drinking simulation: a self-controlled study.
- High-fidelity optical platform for multiplex glutathione profiling links redox dynamics to tumor progression and auxiliary diagnosis.
- Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.
- PMEPA1 promotes gastric cancer cell proliferation by regulating the ubiquitin-mediated degradation of 14-3-3σ and promoting cell cycle progression.
- Exosomal miR-502-5p suppresses the progression of gastric cancer by repressing angiogenesis through the Wnt/β-catenin pathway.
- Facilitating endoscopic full-thickness resection for gastric submucosal tumors with a novel snare traction method (with video).
- A nomogram combining neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) to predict distant metastasis in gastric cancer.
- Single-cell profiling reveals tumour cell heterogeneity accompanying a pre-malignant and immunosuppressive microenvironment in gastric adenocarcinoma.
- Classification of precancerous lesions based on fusion of multiple hierarchical features.
- Gastric Cancer with Sarcopenia: an Area Worth Focusing On.
- Simultaneous incision and suturing of a large wound in the full-layer resection of stromal tumor under the traction of a snare -- a new method of endoscopic suturing.
- Traction and resection in treating gastric submucosal tumor growing extraluminally by using two snares like a ropeway.
- Early gastric mucosa-associated lymphoid tissue lymphoma treated by endoscopic submucosal dissection.
- Systematic evaluation of the safety and therapeutic effects of para-aortic lymphadenectomy for advanced gastric cancer: a systematic review and meta-analysis.
- FLOT1 promotes gastric cancer progression and metastasis through BCAR1/ERK signaling.
- Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell receptor sequencing.
- Incidence trends and survival analysis of appendiceal tumors in the United States: Primarily changes in appendiceal neuroendocrine tumors.
- Comprehensive analysis regarding the prognostic significance of downregulated ferroptosis-related gene AKR1C2 in gastric cancer and its underlying roles in immune response.
- Comparison of endoscopic full-thickness resection and ligation-assisted endoscopic full-thickness resection for small (≤ 1.5 cm) gastric subepithelial tumors originating from muscularis propria.
- The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer.
- miR-511-5p Suppresses Cell Migration, Invasion and Epithelial-Mesenchymal Transition Through Targeting PAK2 in Gastric Cancer.
- Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer.
- E2F5 promotes proliferation and invasion of gastric cancer through directly upregulating UBE2T transcription.
- Extracellular Vesicles Promote the Formation of Pre-Metastasis Niche in Gastric Cancer.
- Study on the Expression of β-1,3-N-acetylglucosaminyltransferase 3 in Gastric Cancer and the Mechanism Promoting Gastric Cancer Progression Based on the Extraction Method of Nanomagnetic Beads.
- Establishment and Validation for Predicting the Lymph Node Metastasis in Early Gastric Adenocarcinoma.
- Identification of a Hypoxia-Angiogenesis lncRNA Signature Participating in Immunosuppression in Gastric Cancer.
- CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer.
- Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy.
- EBV as a high infection risk factor promotes RASSF10 methylation and induces cell proliferation in EBV-associated gastric cancer.
- Endoscopic management of the rare situation where a gastric stromal tumor specimen falls into the nasopharynx.
- Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1.
- Progress of Gastric Cancer Surgery in the era of Precision Medicine.
- Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.
- EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
- The Advantages and Disadvantages of Linear Anastomat and Tubular Anastomat in Radical Gastrectomy of Distal Gastric Cancer
- Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 3.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文5
- Hepatoblastoma-Derived Exosomal FASN Affected the Differentiation of Hepatic Stellate Cells Into Cancer-Associated Fibroblasts by Regulating the Stability of HK2 and Mediating Histone Lactylation.
- Circ-CCT2 Activates Wnt/β-catenin Signaling to Facilitate Hepatoblastoma Development by Stabilizing PTBP1 mRNA.
- LncRNA OIP5-AS1 aggravates the stemness of hepatoblastoma through recruiting PTBP1 to increase the stability of β-catenin.
- miR-126 in Extracellular Vesicles Derived from Hepatoblastoma Cells Promotes the Tumorigenesis of Hepatoblastoma through Inducing the Differentiation of BMSCs into Cancer Stem Cells.
- The Mutual Inhibition of FoxO1 and SREBP-1c Regulated the Progression of Hepatoblastoma by Regulating Fatty Acid Metabolism.
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 6 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
这些数字背后的记录
牵头的论文2
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 6 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
这些数字背后的记录
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 14 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文15
- PLEKHF1 Induces Mitochondrial Dysfunction to Inhibit Osteosarcoma Growth and Metastasis.
- Demethylase, ALKBH1, regulates osteosarcoma chemosensitivity through FZD8/Wnt/β-catenin signaling pathway in the m7G manner.
- Eriodictyol-cisplatin coated nanomedicine synergistically promote osteosarcoma cells ferroptosis and chemosensitivity.
- CYFIP1 coordinate with RNMT to induce osteosarcoma cuproptosis via AURKAIP1 m7G modification.
- Identification and validation of SAC3D1 as a prognostic biomarker promoting the development of osteosarcoma.
- Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways.
- Osteosarcoma neutrophil extracellular trap network-associated gene recurrence and metastasis model.
- The immune cell infiltration-associated molecular subtypes and gene signature predict prognosis for osteosarcoma patients.
- Comprehensive analysis of copper-metabolism-related genes about prognosis and immune microenvironment in osteosarcoma.
- Use of LARS for soft tissue function reconstruction during tumor-type hemi-shoulder replacement achieves a good prognosis: a retrospective cohort study.
- METTL3 upregulates COPS5 expression in osteosarcoma in an m6A-related manner to promote osteosarcoma progression.
- Construction and validation model of necroptosis-related gene signature associates with immunity for osteosarcoma patients.
- Ferroptosis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma.
- circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR-423-5p to activate Wnt5a/Ror2 signaling.
- A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.
早期论文(2016–2020 年)17
- Functionalized BaTiO3 enhances piezoelectric effect towards cell response of bone scaffold.
- miR‑181b‑p53 negative feedback axis regulates osteosarcoma cell proliferation and invasion.
- Letter to the Editor on the article "Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis" (Int J Surg 2019; Nov 15;72:206-213. doi: 10.1016/j.ijsu.2019.11.004. [Epub ahead
- miR-139-mediated NOTCH1 regulation is crucial for the inhibition of osteosarcoma progression caused by resveratrol.
- Rab22a-NeoF1: a promising target for osteosarcoma patients with lung metastasis.
- Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK.
- The possible role of insulin-like growth factor-1 in osteosarcoma.
- MicroRNA-340-5p suppresses osteosarcoma development by down-regulating the Wnt/β-catenin signaling pathway via targeting the STAT3 gene.
- Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics.
- CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613.
- Distraction-suppression effect on osteosarcoma.
- Is double-approach surgery and tenodesis without a gastrocnemius flap better for dealing with proximal fibular osteosarcoma?
- Nd-induced honeycomb structure of intermetallic phase enhances the corrosion resistance of Mg alloys for bone implants.
- MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2.
- Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-κB/IL-6 signals.
- JNK pathway in osteosarcoma: pathogenesis and therapeutics.
- MALAT1 promotes osteosarcoma development by targeting TGFA via MIR376A.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。
长沙有 3 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
- 分期
- 不分期
- 开始
- 2023-02
- 登记号
- NCT05751733
年龄 18 岁 至 未注明(登记的条件)
牵头:中南大学湘雅医院长沙
- 正在招募Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- 分期
- II/III期
- 开始
- 2026-05
- 登记号
- NCT07379047
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- The feasibility of endoscopic resection for esophageal gastrointestinal stromal tumor.
- KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.
- CT-based assessment of sarcopenia for differentiating wild-type from mutant-type gastrointestinal stromal tumor.
- Endoscopic management of the rare situation where a gastric stromal tumor specimen falls into the nasopharynx.
早期论文(2016–2020 年)6
- Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
- Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis.
- [Correlation of CT imaging features and CT texture analysis parameters with pathologic risk stratification in gastric stromal tumors].
- [Option for different surgeries in treating small gastrointestinal stromal tumors].
- Four synchronous primary cancers of the aerodigestive tract and thyroid.
- Concomitant stromal tumor and early cancer of the stomach: What should be done?
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 8 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文4
- HNRNPA2B1 and HNRNPR stabilize ASCL1 in an m6A-dependent manner to promote neuroblastoma progression.
- Exosomal circBBS2 inhibits ferroptosis by targeting miR-494 to activate SLC7A11 signaling in ischemic stroke.
- Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic
- Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer's Disease.
早期论文(2016–2020 年)5
- PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4.
- Exogenous Hydrogen Sulfide Protects SH-SY5Y Cells from OGD/RInduced Injury.
- Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
- [Effect of neuroglobin on oxygen-glucose deprivation and reoxygenation induced autophagy in a human neuroblastoma cell line].
- Genome-wide analysis of DNA methylation during antagonism of DMOG to MnCl2-induced cytotoxicity in the mouse substantia nigra.
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 4 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文8
- Construction of a machine learning-based screening model for IgD myeloma.
- Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1.
- Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
- Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
- Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1.
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
- An interactive nomogram based on clinical and molecular signatures to predict prognosis in multiple myeloma patients.
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 4 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- 分期
- II/III期
- 开始
- 2025-01
- 登记号
- NCT06764238
年龄 1 个月 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛
- 正在招募Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- 分期
- II/III期
- 开始
- 2025-03
- 登记号
- NCT06882057
年龄 1 岁 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.
- Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia.
- Recurrent PAX5::ZCCHC7 rearrangement in B-cell acute lymphoblastic leukemia.
- Chemotherapy vs. "TKI + immunotherapy" in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。
这些数字背后的记录
牵头的论文3
- Alternative Transplantation With Post-Transplantation Cyclophosphamide in Aplastic Anemia: A Retrospective Report From the BMF-WG of Hunan Province, China.
- Association of variations in the Fanconi anemia complementation group and prognosis in Non-small cell lung cancer patients with Platinum-based chemotherapy.
- Haploidentical Peripheral Stem Cell Transplantation for Young Patients with Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide and Methotrexate.
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 4 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 5 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 6 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- 分期
- III期
- 开始
- 2025-03
- 登记号
- NCT06833983
年龄 18 岁 至 65 岁;仅男性(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙
- 正在招募Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- 分期
- II/III期
- 开始
- 2024-01
- 登记号
- NCT06111638
年龄 18 岁 至 未注明;仅男性(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心Xi’an、北京、天津、广州、成都、昆明、武汉、苏州、贵阳、长沙
- 正在招募An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- 分期
- I/II期
- 开始
- 2024-05
- 登记号
- NCT07644832
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心兰州、合肥、太原、济南、西安、郑州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)21
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor
- A Phase I of SS109 in Hemophilia A or and B With Inhibitors
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
- Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
- Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A
- China ADVATE PTP Study
血液疾病
非典型溶血性尿毒症综合征
Atypical haemolytic uraemic syndrome2021–2025 年没有牵头非典型溶血性尿毒症综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 5 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
这些数字背后的记录
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- 分期
- II/III期
- 开始
- 2024-07
- 登记号
- NCT06413654
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙
- 正在招募A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
- 分期
- II期
- 开始
- 2023-05
- 登记号
- NCT06697535
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Lymphoplasmapheresis for Steroid-Refractory Neuromyelitis Optica Spectrum Disorder: A Real-World Multicenter Study in China.
- Analysis of LAP+ and GARP+ Treg subsets in peripheral blood of patients with neuromyelitis optica spectrum disorders.
- Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder.
- Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy?
- Effect of inosine monophosphate dehydrogenase-1 gene polymorphisms on mycophenolate mofetil effectiveness in neuromyelitis optica spectrum disorder patients.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 20 篇,占 4.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 4 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 6
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
- 分期
- II期
- 开始
- 2026-08
- 登记号
- NCT07622342
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、长沙
- 正在招募Myasthenia Gravis Registry in China
- 分期
- 未注明
- 开始
- 2024-02
- 登记号
- NCT06241521
年龄未注明(登记的条件)
牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙
- 正在招募A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- 分期
- II/III期
- 开始
- 2024-07
- 登记号
- NCT06447597
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、长春、长沙
- 正在招募Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- 分期
- III期
- 开始
- 2024-06
- 登记号
- NCT06463587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙
- 正在招募Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- 分期
- II期
- 开始
- 2022-07
- 登记号
- NCT05067348
年龄 18 岁 至 80 岁(登记的条件)
牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙
- 正在招募A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- 分期
- III期
- 开始
- 2021-07
- 登记号
- NCT04951622
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文20
- Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.
- Comparison of Efficacy Between Lymphoplasmapheresis and Plasma Exchange in Myasthenic Crisis.
- Circulating inflammatory proteins as pathogenic mediators and potential therapeutic targets in myasthenia gravis.
- Treatment of juvenile myasthenia gravis with tacrolimus: A cohort study.
- Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.
- Immune repertoire profiling in myasthenia gravis.
- Diagnostic value of antibody concentration ratio for treatment-refractory myasthenia gravis.
- Myasthenia gravis and five autoimmune diseases: a bidirectional Mendelian randomization study.
- Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.
- Pediatric Ocular Myasthenia Gravis: Single-Center Experience.
- Latent tuberculosis infection in myasthenia gravis patients on immunosuppressive therapy: high incidence yet moderate reactivation rate.
- Evidence for genetic causal relationships between gut microbiome, metabolites, and myasthenia gravis: a bidirectional Mendelian randomization study.
- The value of postoperative radiotherapy in thymoma patients with myasthenia gravis.
- Risk factors associated with adverse pregnancy outcomes and postpartum exacerbation in women with myasthenia gravis.
- Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center.
- Poor responses and adverse outcomes of myasthenia gravis after thymectomy: Predicting factors and immunological implications.
- Characteristics of myasthenia gravis in elderly patients: a retrospective study.
- To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.
- Evaluation of outcome measures for myasthenia gravis subgroups.
- Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
- A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Myasthenia Gravis Registry in China
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
- Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
- Study of Telitacicept in Generalized Myasthenia Gravis
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。
这些数字背后的记录
牵头的论文6
- The role of systemic inflammation in the formation and rupture of intracranial aneurysms in moyamoya disease: a retrospective cohort study.
- Risk factors and a novel cerebral infarction extent scoring system for postoperative cerebral ischemia in patients with ischemic Moyamoya disease.
- Development and External Validation of Nomogram for Cerebral Infarction in Moyamoya Diseases.
- Transdural Collateral Circulation Indicates Cerebral Ischemia in Moyamoya Disease.
- A Rare case of central nervous system actinomycosis presenting with moyamoya syndrome.
- High-resolution MRI of the vessel wall helps to distinguish moyamoya disease from atherosclerotic moyamoya syndrome.
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文2
- Clinical and radiological features, treatment responses and prognosis in pediatric patients with co-existing anti-N-methyl-D-aspartate receptor and myelin oligodendrocyte glycoprotein antibody-associated encephalitis: A single center study.
- Clinical features of adult patients with positive NMDAR-IgG coexisting with MOG-IgG.
早期论文(2016–2020 年)5
- A survey on pediatric anti-N-methyl-D-aspartate-receptor encephalitis treatment strategies in China.
- [Cryptococcal Encephalitis Complicating Anti-N-methyl-D-aspartate Receptor Encephalitis in an Immunosuppressed Patient].
- [Clinical features of anti-N-methyl-D-aspartate receptor encephalitis and the concomitant seizure].
- [Clinical analysis of 71 cases of anti-N-methyl-D-aspartate receptor encephalitis in children].
- Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 7 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Clinical characteristics and all-cause mortality in female patients with idiopathic pulmonary fibrosis in Chinese population.
- Smoking and Idiopathic Pulmonary Fibrosis: A Meta-analysis.
- Psoriasis may increase the risk of idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.
- Succinate promotes pulmonary fibrosis through GPR91 and predicts death in idiopathic pulmonary fibrosis.
早期论文(2016–2020 年)4
- Molecular pathogenesis involved in human idiopathic pulmonary fibrosis based on an integrated microRNA‑mRNA interaction network.
- [Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography].
- The effect of H19-miR-29b interaction on bleomycin-induced mouse model of idiopathic pulmonary fibrosis.
- miR‑221 targets HMGA2 to inhibit bleomycin‑induced pulmonary fibrosis by regulating TGF‑β1/Smad3-induced EMT.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 23 篇,占 2.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 4 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
牵头的论文23
- Brain metabolic imaging with 18 F-PET-CT and machine-learning clustering analysis reveal divergent metabolic phenotypes in patients with amyotrophic lateral sclerosis.
- Exploring the Causal Association Between 91 Circulating Inflammatory Proteins and Neurodegenerative Diseases: A Bidirectional Two-Sample Mendelian Randomization and Bioinformatics Analysis.
- Shape Alterations of Subcortical Nuclei Correlate With Amyotrophic Lateral Sclerosis Progression.
- Association of Reduced Brain Metabolism With Motor Function and Survival in Amyotrophic Lateral Sclerosis Patients With Neurofilament Heavy (NEFH) Gene Mutation.
- Retinal alterations induced by amyotrophic lateral sclerosis: An analysis using optical coherence tomography.
- Medulla oblongata dominated synaptic density network degeneration in amyotrophic lateral sclerosis.
- Mutation and clinical analysis of the CLCC1 gene in amyotrophic lateral sclerosis patients from Central South China.
- Association of TRMT2B gene variants with juvenile amyotrophic lateral sclerosis.
- Neutralizing peripheral circulating IL1β slows the progression of ALS in a lentivirus-infected OPTNE478G mouse model.
- Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes.
- Brain metabolic signatures in patients with genetic and nongenetic amyotrophic lateral sclerosis.
- ALS-plus related clinical and genetic study from China.
- Urinary p75ECD levels in patients with amyotrophic lateral sclerosis: a meta-analysis.
- CYLD variants identified in Alzheimer's disease and frontotemporal dementia patients.
- Detection of changes in synaptic density in amyotrophic lateral sclerosis patients using 18 F-SynVesT-1 positron emission tomography.
- Mitochondrial genome variations are associated with amyotrophic lateral sclerosis in patients from mainland China.
- Association of variants in the KIF1A gene with amyotrophic lateral sclerosis.
- Genetics of frontotemporal dementia in China.
- A Step-by-Step Refined Strategy for Highly Efficient Generation of Neural Progenitors and Motor Neurons from Human Pluripotent Stem Cells.
- Downregulation of TOP2 modulates neurodegeneration caused by GGGGCC expanded repeats.
- Spreading of pathological TDP-43 along corticospinal tract axons induces ALS-like phenotypes in Atg5+/- mice.
- Mutation spectrum of amyotrophic lateral sclerosis in Central South China.
- Rare, pathogenic variants in LRP10 are associated with amyotrophic lateral sclerosis in patients from mainland China.
早期论文(2016–2020 年)16
- Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis.
- Mutation analysis of GLT8D1 and ARPP21 genes in amyotrophic lateral sclerosis patients from mainland China.
- Eye tracking metrics to screen and assess cognitive impairment in patients with neurological disorders.
- The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients.
- Advances in genetics research in the pathogenesis of amyotrophic lateral sclerosis.
- [Proteomic analysis of the cerebrospinal fluid from patients with amyotrophic lateral sclerosis based on tandem mass spectrometry technique].
- Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness.
- ALS-Associated E478G Mutation in Human OPTN (Optineurin) Promotes Inflammation and Induces Neuronal Cell Death.
- Identification of CHCHD2 mutations in patients with Alzheimer's disease, amyotrophic lateral sclerosis and frontotemporal dementia in China.
- Mutation analysis of the TIA1 gene in Chinese patients with amyotrophic lateral sclerosis and frontotemporal dementia.
- [Mutations of G38R and D40G cause amyotrophic lateral sclerosis by reducing Annexin A11 protein stability].
- Mutations of CCNF gene is rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia from Mainland China.
- Identification of CHCHD10 Mutation in Chinese Patients with Alzheimer Disease.
- High prevalence of CHCHD10 mutation in patients with frontotemporal dementia from China.
- Genetic and clinical analysis of spinocerebellar ataxia type 36 in Mainland China.
- Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China.
其他疾病
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- A Study of the Safety and Preliminary Efficacy of NKG001 in Pediatric Patients With Type 1 or Type 2 Spinal Muscular Atrophy
- Adult Spinal Muscular Atrophy (SMA) China Registry
- Pediatric Spinal Muscular Atrophy (SMA) China Registry
- Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
其他疾病
法布雷病
Fabry disease2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
其他疾病
庞贝病
Pompe disease2021–2025 年没有牵头庞贝病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 5 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
这些数字背后的记录
牵头的论文3
- Application of long-read sequencing in the diagnosis of Duchenne/Becker muscular dystrophy: unveiling complex structural variations and deep intronic mutations.
- Clinical application of nanopore sequencing for haplotype linkage analysis in preimplantation genetic testing for Duchenne muscular dystrophy.
- Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice.
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
Alport 综合征
Alport syndrome2021–2025 年没有牵头Alport 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 7 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07390123
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心Huangshan City、上海、临沂、北京、湛江、芜湖、西安、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Serum ALCAM is a potential novel non-invasive marker for predicting the progression of IgA nephropathy.
- Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy.
- C5a enhances Vδ1 T cells recruitment via the CCL2-CCR2 axis in IgA nephropathy.
- A Partial Picture of the Single-Cell Transcriptomics of Human IgA Nephropathy.
早期论文(2016–2020 年)11
- Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study.
- Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
- Anaphylatoxins enhance Th9 cell recruitment via the CCL20-CCR6 axis in IgA nephropathy.
- Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.
- Respiratory Syncytial Virus Exacerbates Kidney Damages in IgA Nephropathy Mice via the C5a-C5aR1 Axis Orchestrating Th17 Cell Responses.
- Tonsillitis exacerbates renal injury in IgA nephropathy through promoting Th22 cells chemotaxis.
- NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis.
- Intrinsic renal cells induce lymphocytosis of Th22 cells from IgA nephropathy patients through B7-CTLA-4 and CCL-CCR pathways.
- Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.
- Losartan and Dexamethasone may inhibit chemotaxis to reduce the infiltration of Th22 cells in IgA nephropathy.
- Identification of a novel collagen type IV alpha-4 (COL4A4) mutation in a Chinese family with autosomal dominant Alport syndrome using exome sequencing.
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 4 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 2 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07282353
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- 分期
- II/III期
- 开始
- 2023-02
- 登记号
- NCT05749822
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学西京医院;另有 11 家列出的医院为研究中心Yan’an、北京、南京、天津、广州、成都、昆明、沈阳、西安、郑州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
这些数字背后的记录
联系这家医院
出示给工作人员或司机的院名卡
中南大学湘雅医院
Xiangya Hospital
长沙
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Xiangya Hospital of Central South University; Xiangya Hospital Central South University; XiangYa Hospital; Xiangya Hospital of Central South University (H. Yang); Clinical Anatomy Center of Xiangya Hospital; Xiangya Hospital of Centre-south University; General Surgery of Xiangya Hospital